Clinical Trial Search

Primary: RSV-A Neutralization Antibody Titers Expressed as Geometric Mean Titers (GMTs) — 10060.5; 12255 Titers (ED 60)

Primary: Change From Baseline in the Leicester Cough Questionnaire (LCQ) Total Score at Week 12 — 4.34; 3.59 Scores on a Scale — p=0.034

Primary: Number of Drinks Per Week — 19.7; 23.7 Number of drinks per week — p=0.0130

Primary: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12…

Primary: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12…

Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 19.6; 22.5; 23.1; 15.5 percentage of participants — p=0.1214

Primary: Composite of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, and Non-Fatal Stroke — 327; 292 Participants — p=0.12

Primary: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population — 2.082; 1.994 Liters — p=<0.001

Primary: Change in MADRS Total Score From Baseline to Week 6 — 15.91; 12.04 score on a scale — p=0.002

Primary: Percent of Participants With Hepatitis B Surface Antigen (HBsAg) Loss by Week 240 — 4.1; 5.2 Percentage of participants — p=0.72

Primary: Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05 — 505 Participants

Primary: Postero-anterior (PA) Lumbar Spine Bone Mineral Density by Dual-energy X-ray Absorptiometry (DXA) — 0.90; 0.87 g/cm^2 — p=0.009

Primary: Annualized Bleeding Rate (ABR) for All Bleeding Episodes — 4.19; 1.51 bleeds/year/participants

Primary: Percentage of Participants With a Psoriasis Area and Severity Index 100 (PASI100) Response at Week 16 — 61.7; 48.9 percentage of participants — p=<0.001

Primary: Time to Disease Flare — NA; 27.14 Weeks — p=<0.001